Abstract:Cellular senescence is a permanent state of cell cycle arrest characterized by increased activity of senescence associated β-galactosidase (SA-β-gal). Notably, cancer cells have been also observed to exhibit the senescence response and are being considered for sequential treatment with pro-senescence therapy followed by senolytic therapy. However, there is currently no effective agent targeting β-galactosidase (β-Gal) for imaging cellular senescence and monitoring senolysis in cancer therapy. Aggregation-induced emission luminogen (AIEgen) demonstrates strong fluorescence, good photostability, and biocompatibility, making it a potential candidate for imaging cellular senescence and monitoring senolysis in cancer therapy when endowed with β-Gal-responsive capabilities. In this study, we introduced a β-Gal-activated AIEgen named QM-β-gal for cellular senescence imaging and senolysis monitoring in cancer therapy. QM-β-gal exhibited good amphiphilic properties and formed aggregates that emitted a fluorescence signal upon β-Gal activation. It showed high specificity towards the activity of β-Gal in lysosomes and successfully visualized DOX-induced senescent cancer cells with intense fluorescence both in vitro and in vivo. Encouragingly, QM-β-gal could image senescent cancer cells in vivo for over 14 days with excellent biocompatibility. Moreover, it allowed for the monitoring of senescent cancer cell clearance during senolytic therapy with ABT263. This investigation indicated the potential of the β-Gal-activated AIEgen, QM-β-gal, as an in vivo approach for imaging cellular senescence and monitoring senolysis in cancer therapy via highly specific and long-term fluorescence imaging. STATEMENT OF SIGNIFICANCE: This work reported a β-galactosidase-activated AIEgen called QM-β-gal, which effectively imaged DOX-induced senescent cancer cells both in vitro and in vivo. QM-β-gal specifically targeted the increased expression and activity of β-galactosidase in senescent cancer cells, localized within lysosomes. It was cleared rapidly before activation but maintained stability after activation in the DOX-induced senescent tumor. The AIEgen exhibited a remarkable long-term imaging capability for senescent cancer cells, lasting over 14 days and enabled monitoring of senescent cancer cell clearance through ABT263-induced apoptosis. This approach held promise for researchers seeking to achieve prolonged imaging of senescent cells in vivo.

β-Galactosidase-Activated near-infrared AIEgen for ovarian cancer imaging in vivo

A sensitive fluorescent probe for -galactosidase activity detection and application in ovarian tumor imaging

β-galactosidase instructed in situ self-assembly fluorogenic probe for prolonged and accurate imaging of ovarian tumor

A Specific Near-Infrared Probe for Ultrafast Imaging of Lysosomal β-galactosidase in Ovarian Cancer Cells.

A Novel NIR Fluorescent Probe for Enhanced Β-Galactosidase Detection and Tumor Imaging in Ovarian Cancer Models

A Lysosome-Targetable and Two-Photon Fluorescent Probe for Imaging Endogenous Β-Galactosidase in Living Ovarian Cancer Cells

Debut of a NIR ESIPT-based fluorescent probe with synergistic effects for boosting high-contrast imaging of β-galactosidase in ovarian cancer

First aggregation-induced emission-active probe for species-specific detection of β-galactosidase

Visualize Intracellular Β-Galactosidase Using an Asymmetric Near-Infrared Fluorescent Probe with a Large Stokes Shift

A NIR Fluorescent Probe Based on Tricyanofuran for the Detection of Β-Galactosidase in Living Ovarian Tumor Cells and in Vivo

Aggregation‐induced Emission Luminogens for in Vivo Molecular Imaging and Theranostics in Cancer

NIR-excited Imaging and in Vivo Visualization of ?-Galactosidase Activity Using a Pyranonitrile-Modified Upconversion Nanoprobe

A New Near-Infrared Excitation/emission Fluorescent Probe for the Detection of Β-Galactosidase in Living Cells and in Vivo

Imaging of ovarian cancers using enzyme activatable probes with second near-infrared window emission

NIR-excited imaging and in vivo visualization of β-galactosidase activity using a pyranonitrile-modified upconversion nanoprobe

Real-Time Tracking and in Vivo Visualization of Β-Galactosidase Activity in Colorectal Tumor with a Ratiometric Near-Infrared Fluorescent Probe.

Near-Infrared Aggregation-Induced Emission-Active Probe Enables in Situ and Long-Term Tracking of Endogenous Β-Galactosidase Activity

An Enzyme-Activatable Probe Liberating AIEgens: On-Site Sensing and Long-Term Tracking of Β-Galactosidase in Ovarian Cancer Cells

A Mitochondria-targeted AIEgen Labelled with <SUP>18</SUP>F for Breast Cancer Cell Imaging and Therapy

Design strategies and biological applications of β-galactosidase fluorescent sensor in ovarian cancer research and beyond

Cellular senescence imaging and senolysis monitoring in cancer therapy based on a β-galactosidase-activated aggregation-induced emission luminogen